Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Friday, Feb. 21, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $98.40 to $9,872,759.00.
Highlighted Stocks Traded by Insiders:
Janus Capital Group (JNS) - FREE Research Report Fredericks J Richard who is Director at Janus Capital Group bought 5,000 shares at $10.69 on Feb. 21, 2014. Following this transaction, the Director owned 12,674 shares meaning that the stake was reduced by 65.16% with the 5,000-share transaction.
The shares most recently traded at $11.34, up $0.65, or 5.73% since the insider transaction. Historical insider transactions for Janus Capital Group go as follows:
- 4-Week # shares bought: 26,000
- 12-Week # shares bought: 26,000
- 24-Week # shares bought: 26,000
The average volume for Janus Capital Group has been 3.2 million shares per day over the past 30 days. Janus Capital Group has a market cap of $2.0 billion and is part of the financial sector and financial services industry. Shares are down 10.91% year-to-date as of the close of trading on Friday.
Janus Capital Group, Inc. is a publicly owned asset management holding company with approximately $167.7 billion in assets under management. It also provides retirement planning, investment planning, tax planning, investment for college, and tax planning services to its clients. The stock currently has a dividend yield of 2.58%. The company has a P/E ratio of 17.5. Currently there is 1 analyst that rates Janus Capital Group a buy, 2 analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on JNS - FREE TheStreet Quant Ratings rates Janus Capital Group as a
buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, reasonable valuation levels and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
Janus Capital Group Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Mednax (MD) - FREE Research Report Andreano Dominic J who is SVP, General Counsel and Secy at Mednax sold 3,000 shares at $61.00 on Feb. 21, 2014. Following this transaction, the SVP, General Counsel and Secy owned 16,135 shares meaning that the stake was reduced by 15.68% with the 3,000-share transaction.
The shares most recently traded at $60.79, down $0.21, or 0.35% since the insider transaction. Historical insider transactions for Mednax go as follows:
- 4-Week # shares sold: 9,200
- 12-Week # shares sold: 9,200
- 24-Week # shares sold: 10,695
The average volume for Mednax has been 564,400 shares per day over the past 30 days. Mednax has a market cap of $6.2 billion and is part of the health care sector and health services industry. Shares are up 13.19% year-to-date as of the close of trading on Friday.
MEDNAX, Inc., together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, and other pediatric subspecialties care physician services in the United States and Puerto Rico. The company has a P/E ratio of 22.1. Currently there are 7 analysts that rate Mednax a buy, no analysts rate it a sell, and 5 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MD - FREE TheStreet Quant Ratings rates Mednax as a
buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full
Mednax Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Cavium (CAVM) - FREE Research Report Ali Syed who is Pres., CEO, Chairman of board at Cavium sold 100,000 shares at $40.17 on Feb. 21, 2014. Following this transaction, the Pres., CEO, Chairman of board owned 1.3 million shares meaning that the stake was reduced by 7.3% with the 100,000-share transaction.
Pangrazio Vincent P who is SVP,Gen. Counsel & Secretary at Cavium sold 1,500 shares at $40.00 on Feb. 21, 2014. Following this transaction, the SVP,Gen. Counsel & Secretary owned 9,800 shares meaning that the stake was reduced by 13.27% with the 1,500-share transaction.
The shares most recently traded at $40.58, up $0.58, or 1.43% since the insider transaction. Historical insider transactions for Cavium go as follows:
- 4-Week # shares sold: 100,000
- 12-Week # shares sold: 100,000
- 24-Week # shares sold: 100,000
The average volume for Cavium has been 662,000 shares per day over the past 30 days. Cavium has a market cap of $2.1 billion and is part of the technology sector and electronics industry. Shares are up 16.63% year-to-date as of the close of trading on Friday.
Cavium, Inc. designs, develops, and markets semiconductor processors for intelligent and secure networks. Currently there are 10 analysts that rate Cavium a buy, 1 analyst rates it a sell, and 4 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CAVM - FREE TheStreet Quant Ratings rates Cavium as a
hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full
Cavium Ratings Report from
TheStreet Quant Ratings now.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
